Navigation Links
Facet Solutions' AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
Date:10/22/2007

LOGAN, Utah, Oct. 22 /PRNewswire/ -- Facet Solutions, Inc. announced today that testing conducted by Professor Vijay Goel, PhD., from the Department of Bioengineering at the University of Toledo, demonstrated that the Anatomic Facet Replacement System (AFRS(TM)) has shown biomechanical advantages when compared to dynamic stabilization devices. The objective of the testing was to compare the range of motion, pedicle screw stresses, and spinal stability of facet joint replacement versus dynamic stabilization devices.

An experimentally validated computer model of the spine implanted with the AFRS(TM) demonstrated reduced stresses in the pedicle screws supporting the implant. In addition, the results showed improved motion and structural support to the spine.

"Three inherent characteristics of the AFRS(TM) are thought to contribute to these positive results," stated Professor Goel. "These characteristics are: the anatomic implant design, the unconstrained range of motion, and the replacement of diseased bone with a cobalt chrome implant. Additional testing will be conducted to determine the impact that the AFRS(TM) will have on disc pressures when implanted in the spine."

When treating patients with low back pain, one of the most important concerns for a spine surgeon is how to stabilize the spine after performing a spinal decompression (removal of bone around inflamed nerve roots). In the past, the only option available was a spinal fusion. However, a fusion eliminates motion and may cause the joints adjacent to the fusion to degenerate more quickly. These concerns lead to the development of motion preservation devices like dynamic stabilization and facet joint replacement. Dynamic stabilization is an adjunct to fusion and typically utilizes preloaded rods and screws to provide controlled motion. By contrast, facet joint replacement allows for unconstrained motion and mimics the natural kinematics, balance, and stability in the spine joints; similar to hip and knee joint replacement devices.

Recent studies have shown that the constrained nature of dynamic stabilization increases screw stresses. This increase may have contributed to the higher rates of screw loosening and resulted in limited range of motion. The objective of the biomechanical testing was to determine if the use of an unconstrained implant could potentially eliminate the disadvantages of dynamic stabilization.

Eric Bannon, VP of Clinical and Regulatory Affairs, stated, "The AFRS(TM) was designed with the objective of overcoming the inherent weaknesses of spinal fusion and dynamic stabilization. As a company, we felt it was important to invest in this stringent testing procedure to ensure that the AFRS(TM) would result in positive clinical outcomes. We were pleased to find that our product outperformed spinal fusion and dynamic stabilization in several key areas. The company looks forward to expanding this biomechanical outcome data with results from an ongoing FDA approved IDE Study."

The summary findings from this biomechanical testing will be presented at the Science of Facet Joint Repair and Total Posterior Arthroplasty Symposium which will be held in Austin, Texas at the Omni Hotel on Monday, October 22, 2007 at 6:30 PM.

* Note: AFRS(TM) is an investigational device in the United States. It is

limited by United States (U.S.) Federal Law for investigational use

only.

About Facet Solutions

Facet Solutions, Inc. is a privately held, venture backed company that is focused on developing and commercializing surgical devices for the treatment of facet related spinal disorders. Facet Solutions has received venture capital from its partners De Novo Ventures, Pequot Ventures, and Spray Venture Partners. Facet Solutions is FDA registered and is certified to ISO 13485.


'/>"/>
SOURCE Facet Solutions
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
2. Ties Between Physicians and Drug Companies Still Too Strong: the Prescription Project Offers Solutions to Prevent Conflicts of Interest
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
Breaking Medicine News(10 mins):